Clinical Characteristics of Sarcomatoid HCC in Single Hospital Experience.
- Author:
Hae Kyong CHANG
1
;
Joon Seong PARK
;
Young Nyun PARK
;
Sin Il CHO
;
Kyung Sik KIM
;
Jin Sub CHOI
;
Woo Jung LEE
;
Hoon Sang CHI
;
Byong Ro KIM
;
Dong Sup YOON
Author Information
1. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. yds6110@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Sarcomatoid hepatocellular carcinoma;
Treatment;
Prognosis
- MeSH:
Academic Medical Centers;
Autopsy;
Biopsy;
Carcinoma, Hepatocellular;
Carcinosarcoma;
Chemoradiotherapy, Adjuvant;
Diagnosis;
Drug Therapy;
Follow-Up Studies;
Humans;
Liver;
Prognosis;
Radiotherapy;
Survival Rate
- From:Journal of the Korean Surgical Society
2006;70(3):194-198
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Sarcomatoid hepatocellular carcinoma (HCC) is a rare neoplasm and it has been found in only 1.8% of the surgically resected HCC patients, and in only 3.4~9.4% of the autopsied HCC cases. The pathogenesis of this tumor has't yet been thoroughly clarified, and such a tumor has been variously referred to as spindle cell carcinoma, sarcomatoid carcinoma, pseudosarcoma, or carcinosarcoma. There is only a little difference between the clinical characteristics of the sarcomatoid HCC and those of ordinary HCC. The diagnosis of the sarcomatoid HCC is made by pathological and immunohistochemical techniques after surgical resection, biopsy, or autopsy. METHODS: We reviewed the 10 cases of pathologically confirmed sarcomatoid HCC that were registered at the Yonsei University Medical Center from 1992 to 2004. RESULTS: Surgical operation was performed in seven cases, and curative resection was done only in five. Three patients were treated with chemotherapy or transarterial chemoem-bolization (TACE) with or without concurrent radiotherapy after the diagnosis of sarcomatoid HCC by liver biopsy. Six patients expired within 4 months after the diagnosis. The 6 month and 12 month survival rates for sarcomatoid HCC were 40% and 20%, respectively. The 6 month survival rates for radical resection and non-radical resection were 60% and 0%, respectively. The difference in cumulative survival according to the treatment of sarcomatoid HCC was statistically significant. CONCLUSION: The prognosis of sarcomatoid HCC is very poor; therefore, curative resection, adjuvant chemoradiotherapy, and close follow-up are necessary for patients suffering with sarcomatoid HCC.
